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ABSTRACT
Objectives Mycoplasma genitalium and Chlamydia
trachomatis are the primary pathogens detected from
non-gonococcal urethritis (NGU). In this study, the
efﬁcacy of gatiﬂoxacin was examined against M
genitalium-related urethritis.
Methods The study was an open clinical trial evaluating
the effectiveness of gatiﬂoxacin with 200 mg doses
twice a day for 7 days against male NGU.
Results Between March and September 2008, 169 male
patients were enrolled, and microbiological and clinical
cureratescouldbeevaluatedin86patientsdetectedwith
C trachomatis or M genitalium and in 135 with NGU,
respectively. Microbiological cure rates of gatiﬂoxacin
against C trachomatis and M genitalium were 100% and
83%,respectively,andthetotalclinicalcureratewas99%.
Conclusion Analysis of in-vivo and in-vitro data from the
literature of ﬂuoroquinolone efﬁcacies against M
genitalium suggests that a MIC90 of 0.125 mg/ml or less
may be useful for optimal activity against M genitalium
infection.
The primary pathogens of non-gonococcal
urethritis (NGU) are Chlamydia trachomatis and
Mycoplasma genitalium. The symptoms of chla-
mydial urethritis and M genitalium-related urethritis
are quite similar, and patients with NGU have been
treated upon their ﬁrst visit to clinics without
knowledge of the speciﬁc pathogens underlying
their conditions. In any guidelines, either azithro-
mycin or doxycycline regimens are recommended
for NGU.
1 2 However, previous studies have
demonstrated that doxycycline shows poor efﬁcacy
against M genitalium-related urethritis,
3 whereas
the eradication rates of azithromycin against
M genitalium were approximately 80%.
4 Fluo-
roquinolones show good antichlamydial activity,
much like tetracycline and macrolides. The ability
of moxiﬂoxacin to eradicate azithromycin-resistant
M genitalium at a lower minimum inhibitory
concentration (MIC) has previously been demon-
strated,
4e6 but levoﬂoxacin shows a poor activity.
7
Gatiﬂoxacin is an 8-methoxy ﬂuoroquinolone
that shows a broad spectrum and increased anti-
bacterial activities against Gram-positive cocci
bacteria, anaerobes, chlamydias and mycoplasmas.
8
The antimicrobial activity of gatiﬂoxacin against
M genitalium has been shown to be intermediate
between those of moxiﬂoxacin and levoﬂoxacin.
6 As
gatiﬂoxacin also showed good activities against
Ctrachomatis, it could be usedas apotentialtreatment
regimen for male NGU; thus, we started an open
clinical trial evaluating the effectiveness of gati-
ﬂoxacin in the treatment of NGU. Unfortunately,
gatiﬂoxacin was removed from the US Food and
Drug Administration-approved drug list in
September 2008 due to serious side effects including
abnormal blood glucose levels.
9 The US Food and
Drug Administration determination ultimately
prevented us from completing this study. Regardless
of this, it was decided that this paper would be
published because gatiﬂoxacin was an available
treatment for NGU at the time it was initiated, and
our data provide a potentially useful insight into the
treatment of M genitalium-related urethritis.
MATERIALS AND METHODS
Patients
Male outpatients more than 20 years old, who had
symptoms of urethritis including pus discharge,
micturation pain, urethral discomfort and itching,
were recruited for this study. Patients gave their
written consent and agreed to refrain from sexual
activity without condoms between their ﬁrst and
last visits. Patients were excluded from the study if
they had diabetes mellitus, displayed an allergy to
gatiﬂoxacin, were infected with Neisseria gonor-
rhoeae, were intolerant to gatiﬂoxacin, required
therapy with other antimicrobial agents, had severe
dysfunction of the heart or liver, were treated with
gatiﬂoxacin within the 7 days before the ﬁrst visit
and whose symptoms of urethritis were improving
or who had either a history of or diseases relating to
epilepsy. The clinicians conﬁrmed the selection and
exclusion criteria of the patients for this study and
enrolled patients to a speciﬁed non-proﬁt corpora-
tion, the Supporting Center for Clinical Research
and Education, Osaka, Japan, by fax. This study
was approved by the ethics committee of Osaka
University, Osaka, Japan.
Procedures
Patients with NGU were given a 200 mg dose of
gatiﬂoxacin twice a day for 7 days. On the ﬁrst visit
by patients, clinical symptoms were recorded, the
ﬁrst voided urine of patient was analysed and urine
specimens for microbiological examination were
collected. Patients with less than ﬁve white blood
cells (WBC) per high power ﬁeld in the urinary
sediments or 10 WBC/ml of uncentrifuged urine
specimens were omitted. Patients re-visited the
clinic for evaluation 2e3 weeks after gatiﬂoxacin
treatment and the same procedures as the ﬁrst visit
were performed. Finally, the efﬁcacy of gatiﬂoxacin
was evaluated microbiologically and the clinical
cure rates determined at the re-visit.
Urine collection and microbiological examina-
tions are described below. Approximately 20e30 ml
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Clinicalof ﬁrst voided urine was collected from each patient at least 1 h
after their latest urination. A total of 2 ml from these specimens
was used for the detection of C trachomatis and N gonorrhoeae
using the Aptima Combo2 assay (SRL Co. Ltd., Tokyo, Japan).
Then, 8 ml was stored in a freezer until analysis for M genitalium
and the rest was discarded. Analysis for M genitalium was
performed at the laboratory of urology, Faculty of Medicine,
Miyazaki University, Japan. M genitalium was screened by using
a real-time PCR assay (TaqMan assay) as described by Jensen
et al.
10 Specimens with positive results were re-analysed using
a 16S ribosomal RNA PCR assay for conﬁrmation.
RESULTS
Between March and September 2008, 169 male patients were
enrolled in this study. Among these patients, nine who had had
sexual intercourse without a condom during the study period, 22
who did not participate in follow-up visits, two who used other
antimicrobial agents and one with an adverse effect (diarrhoea)
were omitted. Finally, microbiological and clinical cure rates
could be evaluated in 86 patients detected with C trachomatis or
M genitalium and in 135 with NGU, respectively.
In 135 patients with NGU, C trachomatis and M genitalium
were detected from 53% and 13%, respectively (table 1).
Microbiological cure rates against C trachomatis and M genitalium
were 100% and 83%. M genitalium remained in three patients,
but clinical symptoms were cured with or without the eradi-
cation of M genitalium. Micturition pain and urethral itching
remained in two with chlamydial urethritis after the eradication
of C trachomatis. The total clinical cure rate was 99%.
DISCUSSION
The effectiveness of ﬂuoroquinolones against M genitalium-
related urethritis is varied. Of the ﬂuoroquinolone compounds
tested, the MIC90 values of moxiﬂoxacin, sitaﬂoxacin, gati-
ﬂoxacin, levoﬂoxacin, ciproﬂoxacin and norﬂoxacin were
0.125 mg/ml, 0.125 mg/ml, 0.25 mg/ml, 2 mg/ml, 8 mg/ml and
64 mg/ml, respectively.
6 Of these ﬂuoroquinolones, moxiﬂoxacin,
gatiﬂoxacin and levoﬂoxacin were studied clinically, and their
microbiological efﬁcacies were 100%,
4 83% and 25%,
7 respec-
tively. Assuming that ﬂuoroquinolone tissue levels are equiva-
lent for all drugs in this class, an MIC90 of 0.125 mg/ml or less
may be necessary for optimal activity against M genitalium.
These data may be useful in selecting new ﬂuoroquinolones
for clinical treatment trials in men with NGU, speciﬁcally for
the treatment of M genitalium.M o x i ﬂoxacin is currently not
recommended by any of the various sexually transmitted
infection treatment guidelines for this purpose and should be
studied further in order to be accorded such a recommendation.
In three patients, M genitalium was not eradicated. The
M genitalium DNA loads increased after treatment in only one
case (793e275369 geq). On the last visit, this patient showed no
signs of urethral discharge, although the WBC in the urinary
sediments remained. In two cases, the M genitalium DNA loads
decreased (23373e11 geq, 167020e10 geq), but these specimens
were still positive for M genitalium by 16S rRNA PCR assay.
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Table 1 Microbiological and clinical outcome of gatiﬂoxacin against NGU
Urethritis Pathogens N
Microbiological
outcomes (n[86) Clinical outcomes (n[135)
CT MG Urethral discharge Micturation pain Urethral discomfort Urethral iching
CU CT 68 68/68 e 42/42 33/33 45/46 33/34
CT+MG 4 4/4 4/4 2/2 3/3 2/2 1/1
NCNGU MG 14 e 11/14 12/12 9/9 7/7 7/7
Not detected 48 ee33/33 21/21 33/33 23/23
Indeterminate for CT 1 ee1/1 e 1/1 1/1
Total 135 72/72 15/18 91/91 66/66 90/91 65/66
CT, C trachomatis; CU, chlamydial urethritis; MG, M genitalium; NCNGU, non-chlamydial non-gonococcal urethritis; NGU, non-gonococcal urethritis.
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